480 Biomedical Announces First Human Trial of the Stanza™ Bioresorbable Scaffold in Peripheral Artery Disease

480 Biomedical announced today that it has initiated the first human trial of its groundbreaking Stanza™ self-expanding bioresorbable scaffold for the treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA).... [more]

View complete Press Release article